Evaluation of Minimal Invasive Glaucoma Surgery: Trabeculectomy vs. XEN ® vs. Preserflo ®. Randomized Clinial Trial

Status: Recruiting
Location: See location...
Intervention Type: Device, Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Glaucoma is a neurodegenerative disease with an accelerated and progressiv retinal ganglion cell loss and concomitant visual field defects. Glaucoma can be treated with eye drops, laser therapy or surgery. Various surgical approaches to lower intraocular pressure are available, amongst which trabeculectomy is the gold standard. Recently minimal invasive glaucoma surgery has been introduced and has become a good alternative to trabeculectomy. Randomized clinical trials investigating the postoperative outcomes of various types of glaucoma surgery are limited.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patiens with glaucoma in which surgery is indicated to reach target intraocular pressure

• Subjects not anticipated to require any further surgery in the next 12 months

Locations
Other Locations
Austria
Medical University of Graz
RECRUITING
Graz
Contact Information
Primary
Ewald Lindner, PD Dr.
ewald.lindner@medunigraz.at
+43316385
Time Frame
Start Date: 2021-12-21
Estimated Completion Date: 2025-10
Participants
Target number of participants: 150
Treatments
Active_comparator: Trabeculectomy
Active_comparator: XEN®
Active_comparator: Preserflo®
Sponsors
Leads: Medical University of Graz

This content was sourced from clinicaltrials.gov